The Allergy Billing Cycle
Allergy and immunology billing is more procedure-heavy than most office-based specialties. A single allergy testing encounter can generate 40 to 80 line items, immunotherapy visits create recurring claims across months or years, and biologic medications introduce buy-and-bill or specialty pharmacy workflows that add complexity to every step. The billing process must handle high line-item volume accurately while managing the long-term tracking that immunotherapy and biologic programs demand.
Step 1: Insurance Verification and Prior Authorization
Verify insurance before every visit with special attention to allergy-specific requirements. Many payers require prior authorization for allergy testing panels above a certain size (typically 40 to 60 tests), for immunotherapy initiation, and for all biologic medications. Biologic prior authorizations (omalizumab, dupilumab, mepolizumab) require clinical documentation including failed step therapy, severity scores, and lab results. Submit biologic PAs 10 to 14 days before the planned start date to avoid treatment delays.
For immunotherapy patients, verify coverage at the start of each build-up phase and confirm that the payer covers the specific number of injections planned. Some plans limit immunotherapy duration to 3 years or cap annual injection visits. Identifying these limits upfront prevents denied claims months into treatment.
Step 2: Multi-Test Encounter Coding
Allergy testing encounters require exact unit counts for each test type. After the testing session, the technician or nurse documents the number of percutaneous tests (95004 units), intradermal tests (95024 units), and any controls performed. This documentation drives the charge capture. A 50-allergen percutaneous panel plus 10 intradermal follow-ups generates 50 units of 95004 and 10 units of 95024 on the same claim.
Build a standardized charge capture form or EHR template that requires the exact count of each test type, the specific allergens tested, and the results. Free-text documentation that says “allergy panel performed” without specifying the number and type of tests makes accurate billing impossible and invites audit scrutiny.
Step 3: Immunotherapy Tracking and Billing
Immunotherapy billing requires tracking each patient through build-up and maintenance phases. During build-up, patients receive weekly injections for 3 to 6 months (12 to 24 visits). During maintenance, injections move to every 2 to 4 weeks for 3 to 5 years (36 to 60 additional visits). Each visit generates an injection code (95115 or 95117) and may include a brief E/M if the patient reports reactions or symptoms.
Implement a tracking system that flags overdue patients (missed appointments delay treatment and reduce revenue), monitors vial expiration dates (expired vials require new preparation, generating 95165 charges), and alerts when patients approach payer visit limits. Manual tracking with spreadsheets fails at scale. Use EHR-based immunotherapy modules or dedicated allergy practice management software.
Step 4: Biologic Buy-and-Bill Workflow
Office-administered biologics (omalizumab/Xolair is the most common in allergy) follow the buy-and-bill model. The practice purchases the medication, administers it, and bills the payer for both the drug and the administration. Bill J2357 for omalizumab with the number of units administered and the appropriate administration code (96401 for subcutaneous injection). Drug reimbursement follows ASP+6% under Medicare or contracted rates under commercial plans.
Cash flow management is critical in buy-and-bill. Omalizumab costs $1,000 to $3,000 per dose depending on the patient dosing. The practice must carry the drug inventory cost until reimbursement arrives, typically 20 to 40 days after the claim is processed. Maintain at least 45 days of drug inventory value in working capital and negotiate prompt-pay terms with drug distributors.
Step 5: Claim Submission and Adjudication
Submit claims within 48 hours of service. Allergy testing claims with high line-item counts are more likely to trigger payer edits, so verify that unit counts are consistent across the claim, the diagnosis codes support the tests ordered, and any required modifiers are applied. Common submission errors include listing 95024 without a preceding 95004 session (some payers require percutaneous testing before intradermal) and omitting the modifier 25 on E/M codes billed with testing.
Step 6: Payment Reconciliation
Reconcile allergy payments carefully because per-unit reimbursement makes underpayments harder to spot. If a 40-test percutaneous panel is reimbursed for 35 tests, the dollar difference may be small enough to miss on a summary review. Compare billed units to paid units on every testing claim. For biologic drugs, compare reimbursement against the contracted rate or ASP to confirm the practice is not losing money on drug costs. Flag any claim where drug reimbursement is below acquisition cost for immediate follow-up.